← All trials
NCT06039709
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Jun 30, 2026
- First posted
- Sep 15, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 11
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VirginiaLead sponsor
- University of VirginiaOverall official - principal investigator
- University of VirginiaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.